<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178656</url>
  </required_header>
  <id_info>
    <org_study_id>chenxp007</org_study_id>
    <nct_id>NCT03178656</nct_id>
  </id_info>
  <brief_title>A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis</brief_title>
  <official_title>RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the guidelines recommended, only a few new targeted therapy drugs treatment,
      such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so. According to our
      previous study, patients with hepatic carcinoma without portal vein tumor thrombus backbone
      and the contralateral tumor thrombus applyed tumor excision, along with tumor thrombus, the 3
      year survival rate can reach 39.9%, the 5-year survival rate can reach 22.7%, curative effect
      is obviously better.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival of 1 year</measure>
    <time_frame>1 years</time_frame>
    <description>including 3, 6, and 12 months overall survival (OS) rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival of 3 year</measure>
    <time_frame>3 years</time_frame>
    <description>including 1, 2, and 3 years overall survival (OS) rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>3 years</time_frame>
    <description>deterioration indicated by complications or metastasis detected by CT, MRI and laboratory examination.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mortality</measure>
    <time_frame>30 days</time_frame>
    <description>death within 30 days after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Portal Vein Tumor Thrombus</condition>
  <arm_group>
    <arm_group_label>PVTT WITH SORAFENIB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AASLD recommend therapy:
sorafenib tablet, 400mg, bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVTT WITH OPERATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients suitable for surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>continuous application of the drugs</description>
    <arm_group_label>PVTT WITH SORAFENIB</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>curative resection</description>
    <arm_group_label>PVTT WITH OPERATION</arm_group_label>
    <other_name>trail</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Clinical diagnosis of Hepatic cellular Carcinoma. 2. Patients with Portal Vein
             Tumor Thrombus (PVTT) of Hepatic cellular Carcinoma (HCC) detected by Serum Alpha
             Fetoprotein (AFP) and CT or MRI.

             3. Patients with a solitary tumor or multiple tumor which are resectable. 4. Patients
             without Hepatic vein or bile duct invasion and extrahepatic metastasis.

             5. Patients without surgical contraindication. 6. Patients with Child A or B liver
             function and indocyanine green retention rate at 15min (ICGR15) &lt; 10% before
             treatment.

             7. Laboratory examination: haemoglobin (Hb)&gt;100g/L, white blood cell (WBC) &gt; 3000/mL,
             PLT ＞ 8×10*10/L before treatment.

             8. Patients without severe esophagealgastric varices before treatment. 9. Patients
             with HBV，HBV DNA≤100, 000 copy/mL. 10. All of the patients has written consent for
             this research.

        Exclusion Criteria:

          -  1.Patients with multiple tumors or vascular or bile duct invasion or extrahepatic
             metastasis.

             2.Patients with surgical contraindication. 3.Patients with Child C grade liver
             function before treatment. 4.Patients with other malignancy. 5.Patients treated with
             hepatic resection or TACE before this treatment. 6.Patients with severe
             esophagealgastric varices or refractory ascites or coagulation dysfunction before
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qiong Gong, Doctor</last_name>
    <phone>+8618086496360</phone>
    <email>dtjgq486@hust.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoping Chen, Doctor</last_name>
    <phone>+862783665253</phone>
    <email>chenxp@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatic surgery center, Tong ji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Chen, Doctor</last_name>
      <phone>8602783662851</phone>
      <email>chenxp@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qiong Gong, Doctor</last_name>
      <phone>8618086496360</phone>
      <email>dtjgq486@hust.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>peng zhu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xiaoping Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>sorafenib, operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

